Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases

Beni-Suef University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Cardiovascular Diseases (CVD)

Treatments: Drug: rosuvastatin drug; Combination Product: Patients received rosuvastatin ezetimibe10/10mg

Study type: Interventional

Funder types: Other

Identifiers

NCT07313124

FMBSUREC/05012025/Elsaid

Details and patient eligibility

About

The goal of this clinical trial is to study the efficiency and safety of using combinations of antihyperlipidemic agents with a single drug to treat cardiovascular diseases.

The main questions it aims to answer are:

• Which approach is more effective rosuvastatin monotherapy or rosuvastatin ezetimibe combination antihyperlipidemic for patients with cardiovascular diseases (CVDs)?
• What medical problems do participants could when taking antihyperlipidemic drugs? Researchers will compare rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg to see the effectiveness and safety of these drugs in patients with CVDs.

Participants will:

• Patients will randomize to either rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg.
• Patients will be followed up to 12 weeks after starting treatment.
• All the patients will be subjected to: Full sheet taking, including detailed history and diagnosis of the case, Baseline Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) tests& after 24 weeks of treatment, Lipid Profile, creatine kinase (CK) test, Creatine kinase-MB (CK-MB) test.

Enrollment: 66 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Adults above 18 years, Dyslipidemic patients

Exclusion criteria

Young people under 18 years old pregnant women lactating women Children Hypersensitivity Renal failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

66 participants in 2 patient groups

RosUvastatin

Experimental group

Description:

Patients will receive to rosuvastatin 20 mg

Treatment:

Drug: rosuvastatin drug

rosuvastatin ezetimibe10/10mg.

Active Comparator group

Description:

Patients will receive rosuvastatin ezetimibe10/10mg.

Treatment:

Combination Product: Patients received rosuvastatin ezetimibe10/10mg